CSIMarket
 
Matinas Biopharma Holdings Inc   (MTNB)
Other Ticker:  
 
 
Price: $0.3000 $0.06 25.997%
Day's High: $0.3 Week Perf: 10.7 %
Day's Low: $ 0.24 30 Day Perf: 42.86 %
Volume (M): 3,870 52 Wk High: $ 0.89
Volume (M$): $ 1,161 52 Wk Avg: $0.30
Open: $0.24 52 Wk Low: $0.11



 Market Capitalization (Millions $) 65
 Shares Outstanding (Millions) 217
 Employees 230
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Matinas Biopharma Holdings Inc
Matinas Biopharma Holdings Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative lipid-based pharmaceuticals. The company was founded in 2011 and is headquartered in Bedminster, New Jersey. Matinas Biopharma Holdings Inc. is committed to improving patients' lives by developing products that target unmet medical needs in infectious and inflammatory diseases.

Matinas Biopharma Holdings Inc. is focused on developing its proprietary lipid nanocrystal (LNC) delivery technology, which enables the enhanced absorption and targeted delivery of a wide range of therapeutic agents. The LNC technology is designed to improve the bioavailability of poorly soluble drugs, reduce toxicity, and enhance therapeutic efficacy. It has the potential to significantly impact the treatment of infectious and inflammatory diseases, including HIV/AIDS, hepatitis C, and cryptococcal meningitis.

Matinas Biopharma Holdings Inc. has a broad pipeline of products in development. The lead product candidate is MAT9001, an omega-3 fatty acid-based cardiovascular drug. MAT9001 is a prescription-only, omega-3 free fatty acid drug that is designed to treat patients with high triglycerides, a risk factor for cardiovascular disease. The company is also developing MAT2203, a LNC-formulated amphotericin B drug for the treatment of invasive fungal infections, including aspergillosis and candidiasis. The drug is currently in Phase 2 clinical trials.

The company has a team of experienced leaders and scientists, with expertise in drug development, pharmaceutical manufacturing, clinical research, and regulatory affairs. Matinas Biopharma Holdings Inc. has partnerships and collaborations with leading academic institutions, pharmaceutical companies, and government agencies to accelerate the development of innovative therapeutics.

In summary, Matinas Biopharma Holdings Inc. is a rapidly evolving biopharmaceutical company that is committed to improving the delivery of therapeutic agents for patients suffering from infectious and inflammatory diseases. With a pipeline of products in development and a team of experienced leaders and scientists, the company is well-positioned to create new and innovative treatments that will impact the lives of patients in need.


   Company Address: 1545 Route 206 South Bedminster 7921 NJ
   Company Phone Number: 484-8805   Stock Exchange / Ticker: NYSEAMER MTNB
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Matinas BioPharma's Promising Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program

Published Mon, Feb 26 2024 1:01 PM UTC

This article aims to provide an overview of the positive outcomes reported by Matinas BioPharma on their MAT2203 Compassionate/Expanded Use Access Program. The program enrolled 19 patients with serious and life-threatening invasive fungal infections, encompassing a range of fungal pathogens. Additionally, the company has also made progress towards regulatory approval, as in...

Clinical Study

Matinas BioPharma's MAT2203 Granted Pathway for Single Phase 3 Trial Supporting Potential Breakthrough Treatment for Invasive Aspergillosis

Published Tue, Feb 20 2024 12:30 PM UTC

Matinas BioPharma, a clinical-stage biopharmaceutical company, has recently announced that it has successfully reached an agreement with the U.S. Food and Drug Administration (FDA) for a single Phase 3 registration trial to support the New Drug Application (NDA) for its drug candidate MAT2203. This agreement is a significant milestone in the development of MAT2203 for the tr...

Product Service News

Revolutionizing Inflammatory Disease Treatment: Matinas BioPharma's Oral LNC-Delivered Small Oligonucleotides Show Promise in Groundbreaking Study

Published Wed, Dec 27 2023 12:30 PM UTC

Matinas BioPharma Advances Inflammatory Disease Treatment with Oral LNC-Delivered Small OligonucleotidesIn a groundbreaking study, Matinas BioPharma has demonstrated impressive in vivo biological activity and disease improvement in two inflammatory disease models through the oral delivery of LNC-delivered small oligonucleotides. This exciting research showcases the potential...

Clinical Study

Matinas BioPharma Nearing FDA Alignment for MAT2203 Phase 3 Registration Trial: A Promising Development

Published Thu, Dec 21 2023 12:30 PM UTC

In an exciting development for Matinas BioPharma, the company recently received written preliminary comments from the Food and Drug Administration (FDA) on the Phase 3 registration trial for its leading drug candidate, MAT2203. The feedback moves the company closer to full alignment with FDA expectations, representing a significant milestone in the drug's regulatory and deve...

Shares

Matinas BioPharma Faces NYSE American Continued Listing Deficiency, Takes Swift Action to Address Compliance

Published Fri, Sep 22 2023 9:25 PM UTC


Matinas BioPharma, a clinical-stage biopharmaceutical company known for its groundbreaking lipid nanocrystal (LNC) platform technology, recently announced that it has received a deficiency letter from NYSE American LLC (NYSE American). The letter states that Matinas BioPharma is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com